세계의 국소 진행 췌장암 시장 보고서(2025년)

Locally Advanced Pancreatic Cancer Global Market Report 2025

US $ 4,490 ￦ 6,344,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,170,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,996,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

국소 진행 췌장암 시장 규모는 향후 몇 년 동안 급성장할 것으로 예상됩니다. 예측 기간의 성장은 췌장암에 대한 인식 증가, 화학 치료의 발전, 표적 치료법의 사용 증가, 췌장암 발병률 증가, 병용 치료 프로토콜의 개발, 지원 치료 옵션의 개선 등에 기인할 수 있습니다. 주요 트렌드에는 면역 치료의 발전, 표적 치료법의 개발, 향상된 정밀 방사선 기술, 진단 영상 기술의 개선, 최소 침습적 수술 접근법의 채택, 치료 계획에 인공 지능의 통합, 병용 치료 전략의 발전이 포함됩니다.

담배 소비 증가는 향후 몇 년 동안 국소 진행 췌장암 시장의 성장에 기여할 것으로 예상됩니다. 식물 잎에서 추출한 담배는 일반적으로 담배와 시가와 같은 제품에 사용되며 암 및 심장병과 같은 심각한 건강 상태와 관련된 중독성이 강한 물질인 니코틴을 함유하고 있습니다. 쉬운 접근성, 경제성, 담배 마케팅, 특정 지역의 사회적 수용성, 스트레스 관련 흡연 등 여러 요인이 담배 사용의 증가를 주도하고 있습니다. 흡연은 췌장 악성 종양 발생률을 높이기 때문에 국소 진행 췌장암 발병의 중요한 위험 요인입니다. 예를 들어, 2024년 1월 미국의 흡연 퇴치 비영리 단체인 글로벌 금연 행동에 따르면 2022년 미국 성인 흡연자 수는 약 6,290만 명으로 전 세계에서 네 번째로 높고 미주 지역에서는 가장 높은 수치를 기록했습니다. 또한 미국 성인의 약 11.5%(2,830만 명)가 담배를 피웠으며, 여성(10.1%)에 비해 남성(13.1%)의 유병률이 더 높았습니다. 결과적으로 담배 소비의 증가는 국소 진행 췌장암 시장의 확장을 주도하고 있습니다.

국소 진행 췌장암 시장을 선도하는 기업들은 치료 옵션을 강화하고 환자 치료 결과를 개선하며 이 공격적인 질환과 관련된 미충족 의료 수요를 해결하기 위해 희귀의약품과 같은 혁신적인 제품 개발에 우선순위를 두고 있습니다. 희귀의약품은 제한된 인구에 영향을 미치는 희귀 질환을 치료하기 위해 특별히 고안된 의약품으로, 개발을 장려하기 위해 세제 혜택과 시장 독점권을 포함한 규제 인센티브가 지원됩니다. 예를 들어, 2025년 1월, 미국에 본사를 둔 바이오 제약 회사인 액츄에이트 테라퓨틱스는 자사의 신약인 GSK-3B 억제제 엘라글루시브가 국소 진행 췌장암의 잠재적 형태인 췌관 선암(PDAC) 치료제로 유럽 의약품청(EMA)과 미국 식품의약국(FDA)으로부터 희귀의약품 지정을 받았다고 발표했습니다. 이번 지정은 특히 전이성 PDAC 환자에서 상당한 임상적 개선과 항종양 효과를 입증한 유망한 임상 2상 시험 결과에 이어 이 중증 암 치료의 중요한 격차를 해소할 수 있는 잠재력을 강조한 것입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 국소 진행 췌장암 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 국소 진행 췌장암 시장 : 성장률 분석
• 세계의 국소 진행 췌장암 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 국소 진행 췌장암 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 국소 진행 췌장암 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 국소 진행 췌장암 시장 : 치료별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 화학 치료
• 면역 치료
• 방사선 치료
• 수술
• 세계의 국소 진행 췌장암 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 경구
• 주사제
• 기타 투여 경로
• 세계의 국소 진행 췌장암 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 전문 클리닉
• 연구기관
• 기타 최종 사용자
• 세계의 국소 진행 췌장암 시장 : 화학 치료 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 젬시타빈 기반 화학 치료
• 포르피리녹스 화학 치료
• 세계의 국소 진행 췌장암 시장 : 면역 치료 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 면역 체크 포인트 억제제
• 암 백신
• 세계의 국소 진행 췌장암 시장 : 방사선 치료 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 외부 빔 방사선 치료
• 정위체 방사선 치료(SBRT)
• 세계의 국소 진행 췌장암 시장 : 수술 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 췌십이지장 절제술
• 원위 췌장 절제술
• 전체 췌장 절제술

제7장 지역별 및 국가별 분석

• 세계의 국소 진행 췌장암 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 국소 진행 췌장암 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 국소 진행 췌장암 시장 : 경쟁 구도
• 국소 진행 췌장암 시장 : 기업 프로파일
  • Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • F. Hoffmann-La Roche Ltd. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Merck KGaA 개요, 제품 및 서비스, 전략 및 재무 분석
  • AbbVie Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Bayer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Bristol-Myers Squibb Company
• AstraZeneca plc
• Abbott Laboratories
• Novartis AG
• GSK plc
• Ipsen Biopharmaceuticals Inc.
• Lupin Limited
• NovoCure Limited
• Theratechnologies Inc.
• XBiotech
• Prestige Biopharma
• OSE Immunotherapeutics
• Helix Biopharma Corporation
• Fawn Incorporation
• Eli Lilly and Co

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 국소 진행 췌장암 시장(2029년) : 새로운 기회를 제공하는 국가
• 국소 진행 췌장암 시장(2029년) : 새로운 기회를 제공하는 부문
• 국소 진행 췌장암 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

HBR

영문 목차

영문목차

Locally advanced pancreatic cancer (LAPC) is a stage of pancreatic cancer in which the tumor remains confined to the pancreas and surrounding tissues but has not metastasized to distant organs. Due to its involvement with vital blood vessels or nearby structures, LAPC is typically not suitable for surgical removal.

The primary treatment options for locally advanced pancreatic cancer include chemotherapy, immunotherapy, radiation therapy, and surgery. Chemotherapy uses drugs to destroy cancer cells or inhibit their growth. These therapies can be administered through various routes, including oral, injectable, and others, and are utilized in hospitals, specialty clinics, research institutes, and other healthcare settings.

The locally advanced pancreatic cancer market research report is one of a series of new reports from The Business Research Company that provides locally advanced pancreatic cancer market statistics, including the locally advanced pancreatic cancer industry's global market size, regional shares, competitors with a locally advanced pancreatic cancer market share, detailed locally advanced pancreatic cancer market segments, market trends and opportunities, and any further data you may need to thrive in the locally advanced pancreatic cancer industry. This locally advanced pancreatic cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The locally advanced pancreatic cancer market size has grown rapidly in recent years. It will grow from $0.95 billion in 2024 to $1.05 billion in 2025 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to increased awareness of pancreatic cancer, advancements in chemotherapy regimens, the growing use of targeted therapies, a rising incidence of pancreatic cancer, the development of combination treatment protocols, and enhanced supportive care options.

The locally advanced pancreatic cancer market size is expected to see rapid growth in the next few years. It will grow to $1.57 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to increasing awareness of pancreatic cancer, advancements in chemotherapy regimens, the growing use of targeted therapies, a rising incidence of pancreatic cancer, the development of combination treatment protocols, and improved supportive care options. Major trends include advancements in immunotherapy, the development of targeted therapies, enhanced precision radiation techniques, improvements in diagnostic imaging, the adoption of minimally invasive surgical approaches, the integration of artificial intelligence in treatment planning, and progress in combination therapy strategies.

The rising consumption of tobacco is expected to contribute to the growth of the locally advanced pancreatic cancer market in the coming years. Tobacco, derived from plant leaves, is commonly used in products such as cigarettes and cigars and contains nicotine, a highly addictive substance linked to severe health conditions such as cancer and heart disease. Several factors, including easy access, affordability, tobacco marketing, social acceptance in certain regions, and stress-related smoking, have driven the increase in tobacco use. Tobacco consumption is a significant risk factor for the development of locally advanced pancreatic cancer, as it leads to a higher incidence of pancreatic malignancies. For example, in January 2024, according to Global Action to End Smoking, a US-based non-profit organization dedicated to ending the smoking epidemic, approximately 62.9 million adults in the U.S. used tobacco in 2022, making it the fourth-highest globally and the highest in the Americas. Additionally, around 11.5% of U.S. adults (28.3 million) smoked cigarettes, with a higher prevalence among males (13.1%) compared to females (10.1%). Consequently, the increase in tobacco consumption is driving the expansion of the locally advanced pancreatic cancer market.

Leading companies in the locally advanced pancreatic cancer market are prioritizing the development of innovative products, such as orphan drugs, to enhance treatment options, improve patient outcomes, and address the unmet medical needs associated with this aggressive disease. Orphan drugs are specifically designed to treat rare conditions affecting a limited population and are supported by regulatory incentives, including tax benefits and market exclusivity, to encourage their development. For instance, in January 2025, Actuate Therapeutics Inc., a US-based biopharmaceutical company, announced that its drug Elraglusib, a novel GSK-3B inhibitor, had received Orphan Drug Designation from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of pancreatic ductal adenocarcinoma (PDAC), a potential form of locally advanced pancreatic cancer. This designation underscores its potential to address a critical gap in treating this severe cancer, particularly following promising Phase 2 trial results that demonstrated significant clinical improvements and anti-tumor effects in patients with metastatic PDAC.

In June 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Fusion Pharmaceuticals Inc. for $2.5 billion. This acquisition is intended to strengthen AstraZeneca's oncology portfolio by incorporating advanced radiopharmaceuticals such as FPI-2265, enhancing research and development and manufacturing capabilities, and accelerating the transition to targeted cancer therapies while expanding its presence in Canada. Fusion Pharmaceuticals Inc. is a Canada-based biotechnology company that focuses on developing targeted therapies for various types of cancer, including pancreatic cancer.

Major players in the locally advanced pancreatic cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Bayer Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Ipsen Biopharmaceuticals Inc., Lupin Limited, NovoCure Limited, Theratechnologies Inc., XBiotech, Prestige Biopharma, OSE Immunotherapeutics, Helix Biopharma Corporation, Fawn Incorporation, Eli Lilly and Co.

North America was the largest region in the locally advanced pancreatic cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in locally advanced pancreatic cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the locally advanced pancreatic cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The locally advanced pancreatic cancer market consists of revenues earned by entities by providing services such as chemoradiation, palliative care, targeted therapy, and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The locally advanced pancreatic cancer market also includes sales of CT scanners, MRI machines, brachytherapy systems, needle biopsy devices, and hemodynamic monitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Locally Advanced Pancreatic Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on locally advanced pancreatic cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for locally advanced pancreatic cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The locally advanced pancreatic cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapy: Chemotherapy; Immunotherapy; Radiation Therapy; Surgery
• 2) By Route Of Administration: Oral; Injectables; Other Route Of Administrations
• 3) By End-User: Hospital; Specialty Clinics; Research Institutions; Other End-Users
• Subsegments:
• 1) By Chemotherapy: Gemcitabine-based Chemotherapy; FOLFIRINOX Chemotherapy
• 2) By Immunotherapy: Immune Checkpoint Inhibitors; Cancer Vaccines
• 3) By Radiation Therapy: External Beam Radiation Therapy; Stereotactic Body Radiation Therapy (SBRT)
• 4) By Surgery: Pancreaticoduodenectomy (Whipple Procedure); Distal Pancreatectomy; Total Pancreatectomy
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck KGaA; AbbVie Inc.; Bayer Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Locally Advanced Pancreatic Cancer Market Characteristics

3. Locally Advanced Pancreatic Cancer Market Trends And Strategies

4. Locally Advanced Pancreatic Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Locally Advanced Pancreatic Cancer Growth Analysis And Strategic Analysis Framework

• 5.1. Global Locally Advanced Pancreatic Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Locally Advanced Pancreatic Cancer Market Growth Rate Analysis
• 5.4. Global Locally Advanced Pancreatic Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Locally Advanced Pancreatic Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Locally Advanced Pancreatic Cancer Total Addressable Market (TAM)

6. Locally Advanced Pancreatic Cancer Market Segmentation

• 6.1. Global Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Surgery
• 6.2. Global Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectables
• Other Route Of Administrations
• 6.3. Global Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Specialty Clinics
• Research Institutions
• Other End-Users
• 6.4. Global Locally Advanced Pancreatic Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gemcitabine-based Chemotherapy
• FOLFIRINOX Chemotherapy
• 6.5. Global Locally Advanced Pancreatic Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune Checkpoint Inhibitors
• Cancer Vaccines
• 6.6. Global Locally Advanced Pancreatic Cancer Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy
• Stereotactic Body Radiation Therapy (SBRT)
• 6.7. Global Locally Advanced Pancreatic Cancer Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pancreaticoduodenectomy (Whipple Procedure)
• Distal Pancreatectomy
• Total Pancreatectomy

7. Locally Advanced Pancreatic Cancer Market Regional And Country Analysis

• 7.1. Global Locally Advanced Pancreatic Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Locally Advanced Pancreatic Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Locally Advanced Pancreatic Cancer Market

• 8.1. Asia-Pacific Locally Advanced Pancreatic Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Locally Advanced Pancreatic Cancer Market

• 9.1. China Locally Advanced Pancreatic Cancer Market Overview
• 9.2. China Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Locally Advanced Pancreatic Cancer Market

• 10.1. India Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Locally Advanced Pancreatic Cancer Market

• 11.1. Japan Locally Advanced Pancreatic Cancer Market Overview
• 11.2. Japan Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Locally Advanced Pancreatic Cancer Market

• 12.1. Australia Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Locally Advanced Pancreatic Cancer Market

• 13.1. Indonesia Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Locally Advanced Pancreatic Cancer Market

• 14.1. South Korea Locally Advanced Pancreatic Cancer Market Overview
• 14.2. South Korea Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Locally Advanced Pancreatic Cancer Market

• 15.1. Western Europe Locally Advanced Pancreatic Cancer Market Overview
• 15.2. Western Europe Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Locally Advanced Pancreatic Cancer Market

• 16.1. UK Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Locally Advanced Pancreatic Cancer Market

• 17.1. Germany Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Locally Advanced Pancreatic Cancer Market

• 18.1. France Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Locally Advanced Pancreatic Cancer Market

• 19.1. Italy Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Locally Advanced Pancreatic Cancer Market

• 20.1. Spain Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Locally Advanced Pancreatic Cancer Market

• 21.1. Eastern Europe Locally Advanced Pancreatic Cancer Market Overview
• 21.2. Eastern Europe Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Locally Advanced Pancreatic Cancer Market

• 22.1. Russia Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Locally Advanced Pancreatic Cancer Market

• 23.1. North America Locally Advanced Pancreatic Cancer Market Overview
• 23.2. North America Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Locally Advanced Pancreatic Cancer Market

• 24.1. USA Locally Advanced Pancreatic Cancer Market Overview
• 24.2. USA Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Locally Advanced Pancreatic Cancer Market

• 25.1. Canada Locally Advanced Pancreatic Cancer Market Overview
• 25.2. Canada Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Locally Advanced Pancreatic Cancer Market

• 26.1. South America Locally Advanced Pancreatic Cancer Market Overview
• 26.2. South America Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Locally Advanced Pancreatic Cancer Market

• 27.1. Brazil Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Locally Advanced Pancreatic Cancer Market

• 28.1. Middle East Locally Advanced Pancreatic Cancer Market Overview
• 28.2. Middle East Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Locally Advanced Pancreatic Cancer Market

• 29.1. Africa Locally Advanced Pancreatic Cancer Market Overview
• 29.2. Africa Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Locally Advanced Pancreatic Cancer Market Competitive Landscape And Company Profiles

• 30.1. Locally Advanced Pancreatic Cancer Market Competitive Landscape
• 30.2. Locally Advanced Pancreatic Cancer Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Locally Advanced Pancreatic Cancer Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. AstraZeneca plc
• 31.3. Abbott Laboratories
• 31.4. Novartis AG
• 31.5. GSK plc
• 31.6. Ipsen Biopharmaceuticals Inc.
• 31.7. Lupin Limited
• 31.8. NovoCure Limited
• 31.9. Theratechnologies Inc.
• 31.10. XBiotech
• 31.11. Prestige Biopharma
• 31.12. OSE Immunotherapeutics
• 31.13. Helix Biopharma Corporation
• 31.14. Fawn Incorporation
• 31.15. Eli Lilly and Co

32. Global Locally Advanced Pancreatic Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Locally Advanced Pancreatic Cancer Market

34. Recent Developments In The Locally Advanced Pancreatic Cancer Market

35. Locally Advanced Pancreatic Cancer Market High Potential Countries, Segments and Strategies

• 35.1 Locally Advanced Pancreatic Cancer Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Locally Advanced Pancreatic Cancer Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Locally Advanced Pancreatic Cancer Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료